A novel blood-based assay for treatment monitoring of tuberculosis

BMC Research Notes

Sara Banderby¹  Jacqueline Prieto¹  Erik Södersten¹  Linda Strömqvist Meuzelaar¹  David H. Persing²  Devasena Gnanashanmugam²  Alexandra J. Zimmer³  Morten Ruhwald⁴  Romain Wyss⁴  Anna Mantsoki⁴  Samuel G. Schumacher⁴  Stefano Ongarello⁴  Claudia M. Denkinger⁵  Purvesh Khatri⁶ 

[1] Cepheid AB, Solna, Sweden;Cepheid, Sunnyvale, CA, USA;Departments of Medicine and of Epidemiology, Biostatistics & Occupational Health, McGill University, Montreal, Canada;FIND, Chemin des Mines 9, 1202, Geneva, Switzerland;FIND, Chemin des Mines 9, 1202, Geneva, Switzerland;Division of Tropical Medicine, Center for Infectious Diseases, Heidelberg University Hospital, Heidelberg, Germany;Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, 94305, Stanford, CA, USA;Department of Medicine, Center for Biomedical Informatics Research, Stanford University School of Medicine, 94305, Stanford, CA, USA;

关键词: Tuberculosis;    Host transcriptional signature;    Treatment monitoring;   

DOI  :  10.1186/s13104-021-05663-z

来源: Springer

【 摘 要 】

ObjectivesA novel 3-gene host transcriptional signature (GBP5, DUSP3 and KLF2) has been validated for tuberculosis (TB) treatment monitoring using laboratory-based RNA sequencing platforms. The signature was recently translated by Cepheid into a prototype cartridge-based test that can be run on the GeneXpert instrument. In this study, we prospectively evaluated the change in the expression of the cartridge-based 3-gene signature following treatment initiation among pulmonary TB patients who were microbiologically cured at the end of treatment.ResultsThe 3-gene signature expression level (TB score) changed significantly over time with respect to baseline among 31 pulmonary TB patients. The greatest increase in TB score occurred within the first month of treatment (median fold-increase in TB score: 1.08 [IQR 0.54–1.52]) and plateaued after 4 months of treatment (median TB score: 1.97 [IQR: 1.03–2.33]). The rapid and substantial increase of the TB score in the first month of treatment holds promise for the early identification of patients that respond to TB treatment. The plateau in TB score at 4 months may indicate early clearance of disease and could direct treatment to be shortened. These hypotheses need to be further explored with larger prospective treatment monitoring studies.

【 授权许可】

CC BY